E-cigarettes with a mint flavor are more likely to deteriorate lung health.

Published Date: 24 Apr 2023

Adding mint flavor to e-cigarette liquids increases the amount of vapour particles produced and is linked, according to a recent study published in Respiratory Research.

Read Full News

Latest News

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

Lungcast: Resilience and Sustainability: Preparing Healthcare for the Future with Elizabeth Cerceo, MD Albert Rizzo, MD, Elizabeth Cerceo, MD

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

Long-Term Data Support New Zopapogene Imadenovec Approval for RRP Victoria Johnson

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Nerandomilast Approval Breaks Decade-Long Dry Spell for IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

Mucoactives Found to Have Little Benefit for Bronchiectasis Victoria Johnson

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

FDA Accepts NDA for Chiesi’s Single Inhaler Triple Therapy for Asthma Victoria Johnson

The therapy is currently approved in almost 50 countries under the name Trimbow.

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Todays Updates

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

Progress with Emerging TYK2 Inhibitors for Psoriasis, With Benjamin Lockshin, MD Benjamin Lockshin, MD, FAAD

Benjamin Locksin speaks in this interview about his session titled ‘Encapsulating Progress With New and Emerging TYK2 Inhibitors for Psoriasis.’

Discussing Zasocitinib and Other TYK2 Inhibitors for Psoriasis, With Ronald Vender, MD Ronald Vender, MD

After his sessions on TYK2 Inhibitors for psoriasis and on palmoplantar pustulosis, Vender discussed several key insights in this interview.

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

FDA Clears BrainsWay’s TMS Device for Adolescents with MDD Aged 15 to 21 Years

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Adjunctive Perospirone Safe, Well-Tolerated for MDD in Phase 4 Trial

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Otsuka Pharmaceuticals Submits NDA for Centanafadine to Treat ADHD in Children

Latest News

Exploring the New COPD Era: Biologics, Guidelines, and Real-World Barriers

This episode of Lungcast features a discussion on emerging treatment approaches for SCLC.

New long-term data reveals that Papzimeos offers sustained relief for adults with recurrent respiratory papillomatosis, reducing the need for surgeries.

Maher discussed the new FDA approved drug, marketed as Jascayd, and its impact for idiopathic pulmonary fibrosis.

A recent study reveals that hypertonic saline and carbocisteine do not effectively reduce pulmonary exacerbations.

The therapy is currently approved in almost 50 countries under the name Trimbow.

News All Time

Dupilumab Lessens COPD Exacerbation Impact, with Nicola Hanania, MD, MS Nicola Hanania, MD, MS

Hanania discusses the pooled BOREAS and NOTUS post hoc data showing dupilumab protects lung function before and after COPD exacerbations.

Extended-Release Nalbuphine Improves Patient-Reported Refractory Chronic Cough Within 1 Week Imran Satia, MD, PhD

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

Baseline Type 2 Biomarkers Can Predict Asthma Remission with Dupilumab, with Mario Castro, MD, MPH Kevin Kunzmann

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Dry Powder Treprostinil Tolerated Among Patients with PH-ILD, with Nicholas Kolaitis, MD Kevin Kunzmann

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Aroxybutynin and Atomoxetine (AD109) Reduces Obstructive Sleep Apnea Burden in Phase 3 SynAIRgy Kevin Kunzmann

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

From Slowing Decline to Restoring Function: Taladegib’s Promise in IPF, With Toby Maher, MD, PhD Toby Maher, MD, PhD

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

Dupilumab Reduces Mucus Burden in Uncontrolled Asthma, with Njira Lugogo, MD Njira Lugogo, MD

Mucus plugs are an increasingly present issue in uncontrolled asthma. Lugogo discusses promising findings from VESTIGE that addresses them.

Defining the Future of Asthma Remission, With Linda Rogers, MD

Defining the Future of Asthma Remission, With Linda Rogers, MD

Dupilumab Bests Omalizumab in Airway Improvement for Patients with CRSwNP and Asthma Kevin Kunzmann

Data from the phase 4 head-to-head EVEREST trial further indicates dupilumab's benefit for type 2 inflammatory airway disease.

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

The Asthma and COPD Precision Medicine Era, with Nicola A. Hanania, MD, MS

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Personalized COPD Treatment: Lessons from Biologic Trials and Clinical Practice

Early morning practices linked to less and lower-quality sleep in college athletes

A study using more than 27,000 sleep records of collegiate athletes provides the best evidence to date that early morning team practices take a toll on healthy sleep.

Dreaming of fewer running injuries? Start with better sleep

If you are among the 620 million people who lace up their running shoes on a regular basis, chances are that you're an early riser.

Daylight robbery? How London's skyscrapers deprive marginalized people of light

When you look at the promotional materials advertising luxury high-rise developments in London, it is obvious that the fantasy of living in the sky is fused by a desire for sunlight and "unobstructed" views of the city. Phrases ...

Chronic fatigue syndrome linked to high rates of dysfunctional breathing patterns

Chronic fatigue syndrome leaves patients exhausted and struggling with brain fog—and it typically gets worse after mental or physical exercise, a phenomenon called post-exertional malaise.

Moderate to severe sleep apnea tied to higher risk of brain microbleeds

Research led by Korea University Ansan Hospital reports finding an association between moderate to severe obstructive sleep apnea and increased risk of cerebral microbleeds.

Recommended News For You

Addition of regional nodal irradiation does not decrease rates of invasive breast cancer recurrence, study finds

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

Many patients learn they could have cancer in the emergency department

Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer

Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC

Numerous Oncologists Are Concerned About the Cost of Genomic Testing.

Liver cancer survival rates reflect income disparities

Recommended Articles For You

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025 

Anemia in Older Adults: Causes, Clinical Impact, and Evidence-Based Management 

Anesthetic Techniques and Strategies in Cancer Surgery: Unveiling the Impact on Oncological Outcomes 

The Essential Guide to Understanding Fibrinogen and Its Role in Blood Clotting  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

2.

Year in Review: Non-Small Cell Lung Cancer

3.

EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.

4.

Independent Risk Factors for "Deaths of Despair" Found.

5.

In Relapsed/Refractory Myeloma, Blenrep-Based Regimen Produces PFS Advantage.

1.

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer

2.

Beta-2 Microglobulin: Function, Role in Disease & Clinical Significance Explained

3.

Unmasking the Hidden Symptoms of Ovarian Cancer

4.

Unraveling the Mysteries of Metastasis: Exploring the Latest Advances in Cancer Research

5.

The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option

2.

Oropharyngeal Cancer in Relation to HPV Status

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II

4.

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

5.

Navigating the Complexities of Ph Negative ALL - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot